Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

• Source: NewsAPI.org • 36 words, ~1 min read

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been granted De Novo classification by the U.S. Food & Drug Administration (FDA) for its TESSA Spatial Surgery System. Utilizing cutting-edge accelerated computing …